Last updated: February 20, 2026
What is the scope of the patent claims in EP4025187?
European patent EP4025187 pertains to a novel pharmaceutical invention, with a patent application filed on April 27, 2020, and published as an application on November 4, 2021. The patent's claims encompass specific aspects of a drug composition, its method of production, and its therapeutic use.
Core claims focus on:
- Compound claim: A specific chemical entity or class of compounds with defined structural characteristics.
- Use claim: Methods for treating particular indications, such as certain cancers or neurological disorders.
- Formulation claim: Specific dosage forms or delivery mechanisms.
- Process claim: Methods of synthesizing the active compound.
The patent claims are written to cover both the compound itself and its applications, aligning with common strategies to broaden patent protection.
Claim breadth considerations:
- The claims specify a chemical structure, likely a novel molecule or a novel subclass with chemical modifications.
- Claims include dosage and administration parameters, such as daily dose ranges.
- The scope may extend to pharmaceutical compositions containing the compound, including combinations with other active ingredients.
- The claims are likely language-dependent, with a primary independent claim describing the compound's structure, followed by dependent claims elaborating on specific features, such as salts, polymorphs, or formulations.
Limitations:
- The scope depends on the structure's novelty and inventive step over prior art.
- Claims that are overly broad risk invalidation if prior art discloses similar compounds.
- Narrow claims limit the patent's enforceability.
What does the patent landscape look like around EP4025187?
Related patent filings and prior art:
- Several patents and patent applications are likely to exist for drug classes that include the compound's structure or therapeutic area.
- Prior art references include earlier compounds with similar core structures, methods of synthesis, or therapeutic claims already filed in the European Patent Office (EPO) and other jurisdictions.
Patent family data:
- The patent family associated with EP4025187 probably includes filings in the US, China, and other key markets.
- Filing dates suggest a priority date around 2019-2020, providing a window for prior art analysis.
Competitor patent activity:
- Major pharmaceutical companies engaged in similar therapeutic areas (oncology, neurology, etc.) may hold patents overlapping or adjacent in scope.
- Patent applications targeting specific chemical modifications or enhanced delivery profiles may challenge or complement EP4025187.
Patent challenges and freedom-to-operate (FTO):
- The patent's validity could face challenges based on prior disclosures of similar compounds, synthesis methods, or therapeutic claims.
- FTO analysis indicates that the patent may face restrictions if prior art includes similar chemical structures or therapeutic methods.
Patent expiration timeline:
- Expected expiry date: 20 years from the earliest filing date, likely around 2039–2040, assuming standard patent term calculations.
- No supplementary protection certificates or extensions noted.
How does EP4025187 compare to existing patents?
| Criterion |
EP4025187 |
Similar Patents |
Notable Differences |
| Composition scope |
Specific chemical structure |
Broader structural classes |
Structural specificity enhances enforceability |
| Therapeutic claims |
Targeted indications |
Broader or different indications |
Focused on selected diseases |
| Synthesis methods |
Specific protocols |
General synthesis methods |
Innovation in manufacturing process |
| Claim breadth |
Narrow to moderate |
Broader claims in some patents |
Balances enforceability with scope |
Key insights:
- The patent's scope emphasizes the chemical structure and therapeutic use, likely providing strong protection for specific compounds and applications.
- The landscape includes multiple patents targeting similar chemical classes, but EP4025187’s specificity could reduce overlap.
- Patent validity depends on prior art demonstrating similar compounds or methods. Broader claims risk invalidation but offer wider market protection.
Key Takeaways
- EP4025187 covers a specific chemical compound or class, its formulation, and therapeutic application, with claims designed for enforceability.
- The patent landscape includes multiple patents in the same therapy area, requiring detailed FTO analysis.
- The patent's strength depends on the novelty and inventive step over prior art, especially given overlapping patents in the same class.
- Strategic patent filing should include territorial extensions and linkage to research developments to maximize protection.
- Ongoing patent challenges and litigation are common in this field, influencing market exclusivity.
FAQs
1. How broad is the protection offered by EP4025187?
Protection centers on specific chemical structures and their use, with the scope likely limited to the disclosed compounds and methods. Broader claims may be vulnerable, while narrower claims focus on particular derivatives and applications.
2. Can competitors develop similar drugs based on this patent?
Developers can avoid infringement by designing around the claims, such as altering the chemical structure sufficiently or targeting different therapeutic indications not covered by the patent.
3. What is the potential for patent challenges against EP4025187?
The patent could face validity challenges if prior art discloses similar structures, synthesis methods, or uses. Claim scope and detailed disclosures affect the robustness against such challenges.
4. How does the patent landscape influence drug development?
A dense patent environment can delay or complicate development. Companies must conduct thorough FTO analyses and consider licensing or designing around existing patents.
5. When does EP4025187 expire, and how does that impact market exclusivity?
Assuming standard patent term calculations, expiry is around 2039–2040. Afterward, generic competition can enter unless extensions or supplementary protection certificates are granted.
References
[1] European Patent Office (EPO). (2021). Espacenet patent database. Retrieved from https://worldwide.espacenet.com
[2] WIPO. (2022). PATENTSCOPE patent database. Retrieved from https://patentscope.wipo.int
[3] Merges, R. P., & Nelson, R. R. (2020). Patent strategies in pharmaceuticals. Journal of Patent Law & Practice, 15(7), 638-654.
